Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTaking Wegovy before your next scheduled dose is due raises your exposure to semaglutide above the intended level, increasing the likelihood of nausea, vomiting and other gastrointestinal effects without adding meaningful benefit. Wegovy is a prescription-only medicine; its titration schedule is set by your prescriber, not by how quickly you want results. If you've injected too close to your last dose, don't inject again — read the Patient Information Leaflet and contact a healthcare professional for guidance. The NHS semaglutide medicines page confirms that doses must be taken exactly one week apart, on the same day each week if possible, and that taking an extra dose is not recommended.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide stays active in the body for a long time. Its elimination half-life is approximately seven days, which is precisely why Wegovy is dosed once weekly rather than daily. Steady-state drug levels build gradually over the first four to five weeks of treatment at any given dose. When you inject before the seven-day window has elapsed, semaglutide hasn't cleared enough from your previous dose, and blood levels rise above what the prescriber intended for that stage of titration.
The titration schedule (moving from 0.25mg through 0.5mg, 1mg, 1.7mg, and then to the 2.4mg maintenance dose at roughly four-week steps) exists for this reason. Each lower dose gives your gut receptors time to adjust. Higher circulating levels than expected at any rung of that ladder translate directly into a stronger signal at GLP-1 receptors in the gut wall, which is what drives the nausea and vomiting that many people experience at the start of treatment. Injecting early doesn't accelerate fat loss; the appetite-reduction effect is already active between doses. It simply floods the system faster than the titration plan accounted for.
A common misconception is that the discomfort of side effects means the medicine is "working harder" and that pushing doses closer together will bring quicker results. The clinical evidence doesn't support that. The STEP 1 trial published in the New England Journal of Medicine, which underpins Wegovy's licence, used a strict once-weekly schedule throughout its 68 weeks, the weight outcomes it demonstrated were achieved with consistent intervals, not compressed ones.
The gastrointestinal side-effect profile of semaglutide is well documented. Nausea is the most commonly reported effect, followed by vomiting, diarrhoea, constipation and stomach discomfort. These effects are typically most pronounced when starting treatment or moving to a higher dose, two situations where drug levels are effectively higher relative to what the body has adapted to. An early injection recreates that same scenario mid-schedule.
Practically, you might notice nausea arriving more intensely or earlier after eating. Some people report that foods they'd been tolerating reasonably well suddenly become harder to stomach. Fatigue and headache can follow dehydration if vomiting or diarrhoea is significant. For most people these effects pass within a day or two as levels settle, but they are uncomfortable and avoidable.
One scenario warrants prompt medical attention: severe, persistent stomach pain (particularly pain that radiates towards the back) is a symptom of acute pancreatitis, a rare but serious condition associated with GLP-1 medicines. The MHRA highlighted this in its January 2026 Drug Safety Update on GLP-1 receptor agonists. Pancreatitis risk doesn't vanish between doses; disturbing the intended drug-level curve doesn't help. If this symptom appears, seek urgent medical help rather than waiting to see how things develop. You can also report unexpected side effects through the MHRA Yellow Card scheme.
You can read more about what general effects to expect when you take Wegovy in the normal course of treatment.
Don't inject again. That's the straightforward answer, and it's consistent with standard clinical guidance for missed or misaligned doses of once-weekly semaglutide: do not take a double or corrective dose, and do not try to recalibrate by injecting a third time early. Let the extra dose work through your system.
If the early injection happened within five days of your original scheduled day, the NHS guidance is to take your next dose on your usual day and carry on as normal. If it's within two days of your next scheduled injection, skip that planned dose and resume the week after, effectively sliding your schedule forward by a week. Your prescriber or pharmacist can confirm the right approach for your exact situation, because the calculation depends on how far off the timing was. It's also worth understanding what happens if you take too much Wegovy, so you know which symptoms to watch for while the extra dose clears.
In the meantime, keeping well hydrated matters more than usual given the higher likelihood of nausea. Eating small, plain meals helps reduce gastric irritation. If you're finding food intake harder to manage on Wegovy, smaller portions are usually easier to tolerate on days when GI symptoms are elevated.
Contact your prescribing team if symptoms are severe, if you're unable to keep fluids down, or if you're unsure about your next injection date. At nume, aftercare support runs seven days a week, our team is reachable through the contact page.
The simplest way to prevent this situation recurring is to pick a fixed day of the week for your injection and set a reminder. Many people link it to something they always do, before a weekend walk, on a Monday morning before work. The day matters less than consistency.
Storage is worth checking too. Wegovy pens are kept refrigerated at 2–8°C, and you should always confirm the specific out-of-fridge window in your Patient Information Leaflet before travelling or storing a pen elsewhere. A pen kept at the wrong temperature may appear intact but behave differently, another reason to follow the full instructions rather than improvising. If you want a fuller picture of what happens when you take too much semaglutide, including how the body responds to elevated levels, that detail can help you recognise when something is outside the expected range. If you're uncertain about injection technique, alcohol swabs and proper site rotation are part of the basics your prescriber covers at the outset.
If you're on Wegovy through nume, any concern about your schedule, a misplaced dose, or a side effect that's lasting longer than expected can be raised with our clinical team through the aftercare service. Our clinical team reviews every query personally. For broader background on how semaglutide treatment works, the Wegovy treatment page covers the full picture.
If you're not yet on treatment and want to understand your options, a good starting point is reading about what happens if you take too much semaglutide, which puts the importance of correct dosing in context before you begin. Speak to our prescribers through a free consultation, it's the starting point for finding out whether Wegovy is clinically suitable for you.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.